Antihistamines are often tried, but they usually only work half the time. Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade.

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

That is one of the great benefits of dupilumab (Dupixent) – it has a great safety profile. Some people get an injection site reaction – which goes away quickly – or eye irritation ...

15.61 vs -11.27 Safety results across trials showed injection site reactions to be the most common adverse event with dupilumab (10.3%), which was more frequent than with placebo (8.1%).

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1 ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...